GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Long-Term Debt & Capital Lease Obligation
中文

Nabriva Therapeutics (Nabriva Therapeutics) Long-Term Debt & Capital Lease Obligation : $0.34 Mil (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Nabriva Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.34 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Nabriva Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.34 Mil. Nabriva Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $10.58 Mil. Nabriva Therapeutics's LT-Debt-to-Total-Asset for the quarter that ended in Jun. 2023 was 0.03.

Nabriva Therapeutics's LT-Debt-to-Total-Asset increased from Jun. 2022 (0.01) to Jun. 2023 (0.03). It may suggest that Nabriva Therapeutics is progressively becoming more dependent on debt to grow their business.


Nabriva Therapeutics Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Nabriva Therapeutics's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Long-Term Debt & Capital Lease Obligation Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.72 34.50 5.69 4.27 0.39

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.40 0.39 0.35 0.34

Nabriva Therapeutics Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Nabriva Therapeutics  (OTCPK:NBRVF) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nabriva Therapeutics's LT-Debt-to-Total-Asset ratio for the quarter that ended in Jun. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )/Total Assets (Q: Jun. 2023 )
=0.344/10.578
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Nabriva Therapeutics Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Executives
Hogan H Michael Iii officer: Chief Executive Officer C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio officer: Chief Financial Officer 15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan director
Broom Colin Md officer: Chief Executive Officer 119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow officer: Director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder officer: Chief Executive Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger officer: General Counsel and Corp Sec 633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia officer: Chief Medical Officer C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan officer: Chief Financial Officer C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino officer: Chief Commercial Officer 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty officer: General Counsel & Corp Sec. 1301 2ND AVE, SEATTLE WA 98101